乳腺癌中的肿瘤突变负荷：当前证据、挑战与机遇
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities.
作者信息
Barroso-Sousa Romualdo, Pacífico Jana Priscila, Sammons Sarah, Tolaney Sara M
机构信息
Dasa Institute for Education and Research (IEPD), Brasilia 71635-580, DF, Brazil.
Dasa Oncology, Hospital Brasilia, Brasilia 71635-580, DF, Brazil.
出版信息
Cancers (Basel). 2023 Aug 7;15(15):3997. doi: 10.3390/cancers15153997.
Abstract
Tumor mutational burden (TMB) correlates with tumor neoantigen burden, T cell infiltration, and response to immune checkpoint inhibitors in many solid tumor types. Based on data from the phase II KEYNOTE-158 study, the anti-PD-1 antibody pembrolizumab was granted approval for treating patients with advanced solid tumors and TMB ≥ 10 mutations per megabase. However, this trial did not include any patients with metastatic breast cancer; thus, several questions remain unanswered about the true role of TMB as a predictive biomarker of benefit to immune checkpoint inhibitor therapy in breast cancer. In this review, we will discuss the challenges and opportunities in establishing TMB as a predictive biomarker of benefit to immunotherapy in metastatic breast cancer.
摘要
肿瘤突变负荷（TMB）与许多实体瘤类型中的肿瘤新抗原负荷、T细胞浸润以及对免疫检查点抑制剂的反应相关。基于II期KEYNOTE-158研究的数据，抗PD-1抗体帕博利珠单抗被批准用于治疗晚期实体瘤且TMB≥每兆碱基10个突变的患者。然而，该试验未纳入任何转移性乳腺癌患者；因此，关于TMB作为乳腺癌免疫检查点抑制剂治疗获益预测生物标志物的真正作用，仍有几个问题未得到解答。在本综述中，我们将讨论在转移性乳腺癌中确立TMB作为免疫治疗获益预测生物标志物所面临的挑战和机遇。
相似文献
1
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities.乳腺癌中的肿瘤突变负荷：当前证据、挑战与机遇
Cancers (Basel). 2023 Aug 7;15(15):3997. doi: 10.3390/cancers15153997.
2
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.帕博利珠单抗治疗的晚期实体瘤患者肿瘤突变负荷与结局的相关性：多队列、开放标签、Ⅱ期 KEYNOTE-158 研究的前瞻性生物标志物分析。
Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.
3
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?肿瘤突变负荷作为免疫治疗反应的预测因子：更多是否总是更好？
Clin Cancer Res. 2021 Mar 1;27(5):1236-1241. doi: 10.1158/1078-0432.CCR-20-3054. Epub 2020 Nov 16.
4
Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.每兆碱基 10 个或更多突变的微卫星稳定实体瘤对抗 PD-1 免疫治疗的反应率。
JAMA Oncol. 2021 May 1;7(5):739-743. doi: 10.1001/jamaoncol.2020.7684.
5
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.肿瘤突变负荷预测 pembrolizumab 单药治疗的疗效：一项晚期实体瘤患者的泛肿瘤回顾性分析。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003091.
6
Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.肿瘤突变负荷与突变谱之间的相互作用及其对总生存期的影响：一项接受免疫检查点抑制剂治疗的转移性患者的初步研究
Cancers (Basel). 2022 Nov 4;14(21):5433. doi: 10.3390/cancers14215433.
7
Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.肿瘤突变负荷高的乳腺癌中免疫反应性肿瘤微环境的并发预测因子。
Front Oncol. 2023 Aug 11;13:1235902. doi: 10.3389/fonc.2023.1235902. eCollection 2023.
8
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.肿瘤突变负荷作为实体瘤的预测性生物标志物。
Cancer Discov. 2020 Dec;10(12):1808-1825. doi: 10.1158/2159-8290.CD-20-0522. Epub 2020 Nov 2.
9
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.肿瘤突变负荷高（TMB 高）和微卫星不稳定（MSI）的实际应用证实了它们作为免疫治疗生物标志物的效用。
ESMO Open. 2022 Feb;7(1):100336. doi: 10.1016/j.esmoop.2021.100336. Epub 2021 Dec 23.
10
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
引用本文的文献
1
Precision therapy in metastatic breast cancer: the current landscape of molecular alteration-based therapies.转移性乳腺癌的精准治疗：基于分子改变的治疗现状
Transl Breast Cancer Res. 2025 Jul 16;6:24. doi: 10.21037/tbcr-25-11. eCollection 2025.
2
Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer.乳腺癌中免疫检查点抑制剂反应和耐药的生物标志物。
Breast. 2025 Jul 21;83:104545. doi: 10.1016/j.breast.2025.104545.
3
Exosomal biomarkers and immune checkpoint inhibitors: advancements and future prospects.外泌体生物标志物与免疫检查点抑制剂：进展与未来展望
Cancer Cell Int. 2025 Jun 24;25(1):234. doi: 10.1186/s12935-025-03806-x.
4
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS).纳武利尤单抗联合低剂量伊匹木单抗治疗HER2阴性高微卫星不稳定转移性乳腺癌：一项II期试验（NIMBUS）
Nat Commun. 2025 May 13;16(1):4430. doi: 10.1038/s41467-025-59695-1.
5
Pembrolizumab Monotherapy for Early-Stage Triple-Negative Breast Cancer in a Patient With Lynch Syndrome.帕博利珠单抗单药治疗林奇综合征患者的早期三阴性乳腺癌
JCO Precis Oncol. 2025 Apr;9:e2400646. doi: 10.1200/PO-24-00646. Epub 2025 Apr 28.
6
MHC class II-mediated spontaneous rejection of breast carcinomas expressing model neoantigens.MHC II类分子介导的表达模型新抗原的乳腺癌自发排斥反应。
J Immunother Cancer. 2025 Apr 5;13(4):e010434. doi: 10.1136/jitc-2024-010434.
7
The search for a TNBC vaccine: the guardian vaccine.三阴性乳腺癌疫苗的探索：守护者疫苗。
Cancer Biol Ther. 2025 Dec;26(1):2472432. doi: 10.1080/15384047.2025.2472432. Epub 2025 Mar 15.
8
Different NGS identification methods of somatic mutation sites in solid tumors impact TMB results.实体瘤中体细胞突变位点的不同二代测序鉴定方法会影响肿瘤突变负荷结果。
BMC Cancer. 2025 Mar 10;25(1):427. doi: 10.1186/s12885-025-13719-7.
9
Stroma-derived Dickkopf-1 contributes to the suppression of NK cell cytotoxicity in breast cancer.基质来源的Dickkopf-1有助于抑制乳腺癌中自然杀伤细胞的细胞毒性。
Nat Commun. 2025 Jan 30;16(1):1183. doi: 10.1038/s41467-025-56420-w.
10
Targeting macrophage circadian rhythms with microcurrent stimulation to activate cancer immunity through phagocytic defense.通过微电流刺激靶向巨噬细胞昼夜节律，以通过吞噬防御激活癌症免疫。
Theranostics. 2025 Jan 1;15(2):340-361. doi: 10.7150/thno.100748. eCollection 2025.
本文引用的文献
1
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.帕博利珠单抗单药治疗转移性三阴性乳腺癌患者的生物标志物与临床结局之间的关联：KEYNOTE-086探索性分析
JCO Precis Oncol. 2023 Apr;7:e2200317. doi: 10.1200/PO.22.00317.
2
PI3Kβ controls immune evasion in PTEN-deficient breast tumours.PI3Kβ 控制 PTEN 缺陷型乳腺肿瘤中的免疫逃逸。
Nature. 2023 May;617(7959):139-146. doi: 10.1038/s41586-023-05940-w. Epub 2023 Apr 19.
3
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.PD-L1 阻断联合卡铂作为转移性乳腺 lobular 癌的免疫诱导治疗：GELATO 试验。
Nat Cancer. 2023 Apr;4(4):535-549. doi: 10.1038/s43018-023-00542-x. Epub 2023 Apr 10.
4
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer.基因组复杂性预测激素受体阳性（HR+）/HER2 阴性转移性乳腺癌对内分泌治疗和 CDK4/6 抑制的耐药性。
Clin Cancer Res. 2023 May 1;29(9):1719-1729. doi: 10.1158/1078-0432.CCR-22-2177.
5
The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis.肿瘤突变负担对乳腺癌生存预后的作用：系统评价和荟萃分析。
BMC Cancer. 2022 Nov 17;22(1):1185. doi: 10.1186/s12885-022-10284-1.
6
APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy.激素受体阳性、人表皮生长因子受体 2 阴性乳腺癌中的 APOBEC 突变特征与 CDK4/6 抑制剂和内分泌治疗的不良结局相关。
JCO Precis Oncol. 2022 Oct;6:e2200149. doi: 10.1200/PO.22.00149.
7
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.基于祖源的肿瘤突变负荷重新校准与免疫检查点抑制剂反应的不同临床结局。
Cancer Cell. 2022 Oct 10;40(10):1161-1172.e5. doi: 10.1016/j.ccell.2022.08.022. Epub 2022 Sep 29.
8
Liquid biopsies and tumor mutational burden: the cutoff conundrum.液体活检与肿瘤突变负荷：临界值难题
Nat Med. 2022 Sep;28(9):1753-1754. doi: 10.1038/s41591-022-01999-6.
9
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.阿替利珠单抗对比化疗治疗高血液肿瘤突变负荷的晚期或转移性 NSCLC：BFAST 队列 C 随机 3 期试验的主要分析。
Nat Med. 2022 Sep;28(9):1831-1839. doi: 10.1038/s41591-022-01933-w. Epub 2022 Aug 22.
10
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.帕博利珠单抗联合化疗治疗晚期三阴性乳腺癌。
N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809.
Zotero 插件